Labiotech.eu

Opinion 2 Feb 2023

How digital biomarker assays can harness the power of deep learning from clinical trials to the clinic

By Joe Oakley, MD, medical director of biomarker development, Paige Just as much of medicine has begun to undergo a digital transformation in the past decade, so has pathology. Now, biomarkers, which are indications of particular features of cancer and are essential to diagnosis and treatment, are beginning their own digital revolution. This is an […]

February 2, 2023 - 8 minutesmins - By External Contributor

News and Trends 2 Feb 2023

Crown Bioscience acquiring Indivumed’s service business and biobank

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH. A share purchase agreement (SPA) between was executed in December, 2022, and subject to customary closing adjustments, the transaction is expected to close in April 2023. Indivumed […]

February 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

Orbit Discovery and Endevica Bio to develop cachexia therapeutics

Orbit Discovery Limited has entered into a multi target research agreement with Endevica Bio Inc. Endevica creates first-in-class therapeutics for cachexia caused by cancer and other chronic conditions. Its lead compound has proven to be safe and well-tolerated in phase 1 trials. The collaboration aims to accelerate Endevica’s development of advanced G-protein coupled receptor (GPCR)-targeting […]

February 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

Almost 20% of cancer trials have recruited only one patient

Phesi Inc., a global provider of clinical development data analytics, has published an analysis of site-level enrolment data from 173 cancer clinical trials conducted in the past three years. The data, spanning 83,916 cancer patients from 57 countries, reveals that of the 11,826 investigator sites participating in these trials, 2,298 (19%) enrolled just one patient […]

February 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

Recurv Pharma receives funding for cancer therapy development

Recurv Pharma Inc. is receiving up to $24 million in funding from TVM Capital Life Science through its TVM Life Science Innovation II SCSp fund. Recurv Pharma plans to develop a novel taxane therapy to treat solid tumors to the proof-of-concept stage. The U.S. based biotech firm is the eighth early-stage or project-focused company (PFC) […]

February 2, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

Possible drug targets from Korean atherosclerosis research

Research suggests that the enzyme phosphoenolpyruvate carboxykinase 2 (PCK2) and its gene play a role in the development of vascular injury and atherosclerosis. Atherosclerosis is a deadly disease; research suggests that proliferation of vascular smooth muscle cells (VSMCs) and formation of a neointimal layer along the inner lining of arteries play a major role in […]

February 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

AstraZeneca creates FRAGLER for DNA synthesis

“Plasmids are critical for so many processes in early drug discovery,” says David Öling, associate principal scientist at AstraZeneca. “From protein production, cell line engineering, CAR-T cell therapy, viral vector generation, therapeutic genome editing, mRNA/vaccine production and more. The time it takes and the cost of producing plasmids for DNA constructs is a critical limiting […]

February 2, 2023 - 6 minutesmins - By Jim Cornall

Interview 1 Feb 2023

Foundation for the National Institutes of Health: partnering to tackle cancer

The Foundation for the National Institutes of Health (FNIH) takes on cancer through public-private research partnerships on prevention and early diagnosis. Dr Stacey Adam is associate vice president for research partnerships at the Foundation for the National Institutes of Health. In her role, she leads the cancer research partnership programs. Adam is a molecular pharmacologist/cancer […]

February 1, 2023 - 8 minutesmins - By Jim Cornall

In Depth 1 Feb 2023

The future of cancer treatment: Exploiting cancer’s key vulnerabilities

By Victoria Zazulina, M.D., head of development unit, oncology, for the healthcare business of Merck Since 2000, February 4 has been recognized as World Cancer Day and marked by efforts across the globe to raise awareness of the disease’s devastating impact and encourage efforts to improve prevention, detection and treatment. Over the past two decades, […]

February 1, 2023 - 4 minutesmins - By External Contributor

In Depth 1 Feb 2023

Expanding the world of biomarkers with proteogenomics

By Michael Pisano, executive vice president, proteomics, Discovery Life Sciences In oncology, characterizing genetic markers is a powerful tool, but it only tells part of the story. A burgeoning field called proteogenomics is helping uncover downstream biomarkers that represent the functional changes resulting from gene expression that will launch research and development of new, targeted […]

February 1, 2023 - 7 minutesmins - By External Contributor

News and Trends 1 Feb 2023

How can patients have access to the latest science?

Innovation in cancer research is happening at an accelerated rate, but the current healthcare system is not equipped to ensure patients can quickly access the latest science. There is a disconnect between treatment innovation and clinical practice. Most cancer patients are seen at community hospitals and treated by generalist oncologists, and data shows that a […]

February 1, 2023 - 6 minutesmins - By Jim Cornall

In Depth 1 Feb 2023

Cancer: what are the barriers to research?

Everyone imagines a world without cancer, but getting there is difficult. With World Cancer Day coming up on February 4, we took the opportunity to ask some life science company CEOs, CMOs, and chief scientific officers the same question about cancer research. We asked CellCentric CEO, Will West; iOnctura CEO, Catherine Pickering; ISA Pharmaceuticals chief […]

February 1, 2023 - 6 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

How digital biomarker assays can harness the power of deep learning from clinical trials to the clinic

Crown Bioscience acquiring Indivumed’s service business and biobank

Orbit Discovery and Endevica Bio to develop cachexia therapeutics

Almost 20% of cancer trials have recruited only one patient

Recurv Pharma receives funding for cancer therapy development

Possible drug targets from Korean atherosclerosis research

AstraZeneca creates FRAGLER for DNA synthesis

Foundation for the National Institutes of Health: partnering to tackle cancer

The future of cancer treatment: Exploiting cancer’s key vulnerabilities

Expanding the world of biomarkers with proteogenomics

How can patients have access to the latest science?

Cancer: what are the barriers to research?

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!